Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Since the killing of UnitedHealth Group’s top insurance executive and the outpouring of public frustration with delayed and denied care that followed, a major question
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The FDA has reaffirmed that the shortage of Eli Lilly’s blockbuster obesity and diabetes medications is resolved, dealing a blow to pharmacies and telehealth services
After a tough few years, healthcare startups are entering 2025 with cautious optimism. Twelve months ago, early-stage startups faced a funding cliff … Sign up
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Through a new relationship with Eli Lilly, Ro patients can now get easier access to the drugmaker’s discounted, single-dose vials of blockbuster obesity drug Zepbound